

Resource Summary Report

Generated by [NIF](#) on Aug 3, 2026

CellMinerCDB

RRID:SCR_025649

Type: Tool

Proper Citation

CellMinerCDB (RRID:SCR_025649)

Resource Information

URL: <https://discover.nci.nih.gov/rsconnect/cellminercdb/>

Proper Citation: CellMinerCDB (RRID:SCR_025649)

Description: Web application integrating cancer cell line pharmacogenomics. Enables exploration and analysis of cancer cell line pharmacogenomic data across different sources. Focuses on cancer patient-derived human cell line molecular and pharmacological data. CellMinerCDB (v1.2) includes several improvements.

Synonyms: , Cell Miner CDB, CellMiner Cross-Database, CellMinerCDB 1.2

Resource Type: web application, software resource

Defining Citation: [PMID:30553813](#), [PMID:30553813](#)

Keywords: integrating cancer cell line pharmacogenomics, exploration and analysis of cancer cell line pharmacogenomic data, exploration and analysis, cancer cell line, pharmacogenomic data

Funding: NIGMS P41 GM103504;
NCI

Availability: Free, Freely available,

Resource Name: CellMinerCDB

Resource ID: SCR_025649

Record Creation Time: 20240824T053240+0000

Record Last Update: 20260803T040901+0000

Ratings and Alerts

No rating or validation information has been found for CellMinerCDB.

No alerts have been found for CellMinerCDB.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 11 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Masood MBE, et al. (2025) Integrated pan-cancer analysis revealed therapeutic targets in the ABC transporter protein family. PloS one, 20(5), e0308585.

Reinhold WC, et al. (2025) Acetalax and Bisacodyl for the Treatment of Triple-Negative Breast Cancer: A Combined Molecular and Preclinical Study. Cancer research communications, 5(2), 375.

Li C, et al. (2025) Anticancer drug synergy prediction based on CatBoost. PeerJ. Computer science, 11, e2829.

Smith NJ, et al. (2025) Differentiation signals induce APOBEC3A expression via GRHL3 in squamous epithelia and squamous cell carcinoma. The EMBO journal, 44(1), 1.

Li J, et al. (2025) Protocol for tumor prognostic prediction, molecular stratification, and target discovery using a machine learning-driven approach. STAR protocols, 6(4), 104130.

Onji H, et al. (2024) Schlafen 11 further sensitizes BRCA-deficient cells to PARP inhibitors through single-strand DNA gap accumulation behind replication forks. Oncogene, 43(32), 2475.

Mizunuma M, et al. (2024) Acetalax (Oxyphenisatin Acetate, NSC 59687) and Bisacodyl Cause Oncosis in Triple-Negative Breast Cancer Cell Lines by Poisoning the Ion Exchange Membrane Protein TRPM4. Cancer research communications, 4(8), 2101.

Nakasuka F, et al. (2024) The role of cytidine 5'-triphosphate synthetase 1 in metabolic rewiring during epithelial-to-mesenchymal transition in non-small-cell lung cancer. FEBS open bio, 14(9), 1570.

Chen P, et al. (2021) Aberrant methylation modifications reflect specific drug responses in small cell lung cancer. Genomics, 113(3), 1114.

Jo U, et al. (2021) Novel and Highly Potent ATR Inhibitor M4344 Kills Cancer Cells With Replication Stress, and Enhances the Chemotherapeutic Activity of Widely Used DNA Damaging Agents. Molecular cancer therapeutics, 20(8), 1431.

Yao X, et al. (2020) A membrane transporter determines the spectrum of activity of a potent platinum-acridine hybrid anticancer agent. Scientific reports, 10(1), 15201.